Dévina C. Ung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dévina C. Ung has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Laumonnier
Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France
5 shared publications - Annick Toutain
Department of Genetics, Bretonneau University Hospital, Tours, France
3 shared publications Andjela Zlatanovic
Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine, Paris, France
2 shared publicationsBassam Abu-Libdeh
Department of Pediatrics, Makassed Hospital and Faculty of Medicine, Al-Quds University, East Jerusalem, Jerusalem, Palestine
2 shared publications- Bertrand Lambolez
Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine - Institut de Biologie Paris Seine (NPS-IBPS)
2 shared publications - Giovanni Stevanin
Bordeaux University, CNRS, INCIA, UMR 5287, NRGen Team, 33076 Bordeaux, France
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1199
Organoids and Spheroids for the Design and the Evaluation of Therapeutic Strategies
The design and the evaluation of effective therapeutic modalities have long relied on experimental models that only partially reproduce human physiology
- 22 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1199
Open AccessOrganoids and Spheroids for the Design and the Evaluation of Therapeutic Strategies
The design and the evaluation of effective therapeutic modalities have long relied on experimental models that only partially reproduce human physiology
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Récepteurs synaptiques et troubles du neuro-développement : approches translationnelles pour la caractérisation fonctionnelle des gènes PTCHD1 et GRID1
L’autisme et la déficience intellectuelle (DI) définissent un spectre de troubles neuro-développementaux à composante génétique significative et impliquant au moins 1% de la population générale. Suite à l’identification de mutations dans les gènes PTCHD1 et GRID1 chez des sujets avec autisme et/ou DI, nous avons étudié leur rôle neuro-développemental par des approches translationnelles en modèle cellulaire et/ou animal Nos résultats montrent que PTCHD1 est un nouveau récepteur post-synaptique dont l'inactivation chez la souris Ptchd1-/y induit des troubles comportementaux et un dysfonctionnement des synapses glutamatergiques. En outre, PTCHD1 interagit avec les protéines PSD95, SAP102 (protéome postsynaptique glutamatergique), et RAC1 (cytosquelette d'actine et voie RhoGTPase). Concernant le gène GRID1, l’étude fonctionnelle in vitro d’une mutation homozygote (Arg161His) associée à une DI a révélé des altérations de la morphologie neuronale et synaptique, et souligne le rôle essentiel de ce récepteur sur la formation des terminaisons présynaptiques excitatrices. Ces données fournissent de nouveaux éléments sur les mécanismes physiopathologiques impliqués dans l’autisme et la DI, soulignant le rôle essentiel des récepteurs de la synapse excitatrice glutamatergique dans la cognition et la communication.
- 2 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Récepteurs synaptiques et troubles du neuro-développement : approches translationnelles pour la caractérisation fonctionnelle des gènes PTCHD1 et GRID1
L’autisme et la déficience intellectuelle (DI) définissent un spectre de troubles neuro-développementaux à composante génétique significative et impliquant au moins 1% de la population générale. Suite à l’identification de mutations dans les gènes PTCHD1 et GRID1 chez des sujets avec autisme et/ou DI, nous avons étudié leur rôle neuro-développemental par des approches translationnelles en modèle cellulaire et/ou animal Nos résultats montrent que PTCHD1 est un nouveau récepteur post-synaptique dont l'inactivation chez la souris Ptchd1-/y induit des troubles comportementaux et un dysfonctionnement des synapses glutamatergiques. En outre, PTCHD1 interagit avec les protéines PSD95, SAP102 (protéome postsynaptique glutamatergique), et RAC1 (cytosquelette d'actine et voie RhoGTPase). Concernant le gène GRID1, l’étude fonctionnelle in vitro d’une mutation homozygote (Arg161His) associée à une DI a révélé des altérations de la morphologie neuronale et synaptique, et souligne le rôle essentiel de ce récepteur sur la formation des terminaisons présynaptiques excitatrices. Ces données fournissent de nouveaux éléments sur les mécanismes physiopathologiques impliqués dans l’autisme et la DI, soulignant le rôle essentiel des récepteurs de la synapse excitatrice glutamatergique dans la cognition et la communication.
- Open Access
- 27 July 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 176, 106307
The PTCHD1 protein: A prominent actor in brain function and in neurodevelopmental disorders
- 27 July 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 176, 106307
Open AccessThe PTCHD1 protein: A prominent actor in brain function and in neurodevelopmental disorders
- Open Access
- 28 February 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (4) , 1205-1215
GRID1/GluD1 homozygous variants linked to intellectual disability and spastic paraplegia impair mGlu1/5 receptor signaling and excitatory synapses
The ionotropic glutamate delta receptor GluD1, encoded by the GRID1 gene, is involved in synapse formation, function, and plasticity. GluD1 does not bind glutamate, but instead cerebellin and D-serine, which allow the formation of trans-synaptic bridges, and trigger transmembrane signaling. Despite wide expression in the nervous system, pathogenic GRID1 variants have not been characterized in humans so far. We report homozygous missense GRID1 variants in five individuals from two unrelated consanguineous families presenting with intellectual disability and spastic paraplegia, without (p.Thr752Met) or with (p.Arg161His) diagnosis of glaucoma, a threefold phenotypic association whose genetic bases had not been elucidated previously. Molecular modeling and electrophysiological recordings indicated that Arg161His and Thr752Met mutations alter the hinge between GluD1 cerebellin and D-serine binding domains and the function of this latter domain, respectively. Expression, trafficking, physical interaction with metabotropic glutamate receptor mGlu1, and cerebellin binding of GluD1 mutants were not conspicuously altered. Conversely, upon expression in neurons of dissociated or organotypic slice cultures, we found that both GluD1 mutants hampered metabotropic glutamate receptor mGlu1/5 signaling via Ca2+ and the ERK pathway and impaired dendrite morphology and excitatory synapse density. These results show that the clinical phenotypes are distinct entities segregating in the families as an autosomal recessive trait, and caused by pathophysiological effects of GluD1 mutants involving metabotropic glutamate receptor signaling and neuronal connectivity. Our findings unravel the importance of GluD1 receptor signaling in sensory, cognitive and motor functions of the human nervous system.
- 28 February 2024
- Published by Springer Nature in Molecular Psychiatry
- Vol. 29 (4) , 1205-1215
Open AccessGRID1/GluD1 homozygous variants linked to intellectual disability and spastic paraplegia impair mGlu1/5 receptor signaling and excitatory synapses
The ionotropic glutamate delta receptor GluD1, encoded by the GRID1 gene, is involved in synapse formation, function, and plasticity. GluD1 does not bind glutamate, but instead cerebellin and D-serine, which allow the formation of trans-synaptic bridges, and trigger transmembrane signaling. Despite wide expression in the nervous system, pathogenic GRID1 variants have not been characterized in humans so far. We report homozygous missense GRID1 variants in five individuals from two unrelated consanguineous families presenting with intellectual disability and spastic paraplegia, without (p.Thr752Met) or with (p.Arg161His) diagnosis of glaucoma, a threefold phenotypic association whose genetic bases had not been elucidated previously. Molecular modeling and electrophysiological recordings indicated that Arg161His and Thr752Met mutations alter the hinge between GluD1 cerebellin and D-serine binding domains and the function of this latter domain, respectively. Expression, trafficking, physical interaction with metabotropic glutamate receptor mGlu1, and cerebellin binding of GluD1 mutants were not conspicuously altered. Conversely, upon expression in neurons of dissociated or organotypic slice cultures, we found that both GluD1 mutants hampered metabotropic glutamate receptor mGlu1/5 signaling via Ca2+ and the ERK pathway and impaired dendrite morphology and excitatory synapse density. These results show that the clinical phenotypes are distinct entities segregating in the families as an autosomal recessive trait, and caused by pathophysiological effects of GluD1 mutants involving metabotropic glutamate receptor signaling and neuronal connectivity. Our findings unravel the importance of GluD1 receptor signaling in sensory, cognitive and motor functions of the human nervous system.
- Open Access
GRID1/ GluD1 homozygous variants linked to intellectual disability and spastic paraplegia impair mGlu1/5 receptor signaling and excitatory synapses
The ionotropic glutamate delta receptor GluD1, encoded by the GRID1 gene, is involved in synapse formation, function, and plasticity. GluD1 does not bind glutamate, but instead cerebellin and D-serine, which allow the formation of trans-synaptic bridges, and trigger transmembrane signaling. Despite wide expression in the nervous system, pathogenic GRID1 variants have not been characterized in humans so far. We report homozygous missense GRID1 variants in five individuals from two unrelated consanguineous families presenting with intellectual disability and spastic paraplegia, without (p.Thr752Met) or with (p.Arg161His) diagnosis of glaucoma, a threefold phenotypic association whose genetic bases had not been elucidated previously. Molecular modeling indicated that Arg161His and Thr752Met mutations alter the hinge between GluD1 cerebellin and D-serine binding domains and the stiffness of this latter domain, respectively. Expression, trafficking, physical interaction with metabotropic glutamate receptor mGlu1, and cerebellin binding of GluD1 mutants were not conspicuously altered. Conversely, we found that both GluD1 mutants hampered signaling of metabotropic glutamate receptor mGlu1/5 via the ERK pathway in neurons of primary cortical culture. Moreover, both mutants impaired dendrite morphology and excitatory synapse density in neurons of primary hippocampal culture. These results show that the clinical phenotypes are distinct entities segregating in the families as an autosomal recessive trait, and caused by pathophysiological effects of GluD1 mutants involving metabotropic glutamate receptor signaling and neuronal connectivity. Our findings unravel the importance of the GluD1 receptor signaling in sensory, cognitive and motor functions of the human nervous system.
Open AccessGRID1/ GluD1 homozygous variants linked to intellectual disability and spastic paraplegia impair mGlu1/5 receptor signaling and excitatory synapses
The ionotropic glutamate delta receptor GluD1, encoded by the GRID1 gene, is involved in synapse formation, function, and plasticity. GluD1 does not bind glutamate, but instead cerebellin and D-serine, which allow the formation of trans-synaptic bridges, and trigger transmembrane signaling. Despite wide expression in the nervous system, pathogenic GRID1 variants have not been characterized in humans so far. We report homozygous missense GRID1 variants in five individuals from two unrelated consanguineous families presenting with intellectual disability and spastic paraplegia, without (p.Thr752Met) or with (p.Arg161His) diagnosis of glaucoma, a threefold phenotypic association whose genetic bases had not been elucidated previously. Molecular modeling indicated that Arg161His and Thr752Met mutations alter the hinge between GluD1 cerebellin and D-serine binding domains and the stiffness of this latter domain, respectively. Expression, trafficking, physical interaction with metabotropic glutamate receptor mGlu1, and cerebellin binding of GluD1 mutants were not conspicuously altered. Conversely, we found that both GluD1 mutants hampered signaling of metabotropic glutamate receptor mGlu1/5 via the ERK pathway in neurons of primary cortical culture. Moreover, both mutants impaired dendrite morphology and excitatory synapse density in neurons of primary hippocampal culture. These results show that the clinical phenotypes are distinct entities segregating in the families as an autosomal recessive trait, and caused by pathophysiological effects of GluD1 mutants involving metabotropic glutamate receptor signaling and neuronal connectivity. Our findings unravel the importance of the GluD1 receptor signaling in sensory, cognitive and motor functions of the human nervous system.
- Open Access
- 1 December 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 90 (11) , 742-755
Developmental and Behavioral Phenotypes in a Mouse Model of DDX3X Syndrome
- 1 December 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 90 (11) , 742-755
Open AccessDevelopmental and Behavioral Phenotypes in a Mouse Model of DDX3X Syndrome
- 1 October 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 485, 218-223
Whole genome sequencing identifies a de novo 2.1 Mb balanced paracentric inversion disrupting FOXP1 and leading to severe intellectual disability
- 1 October 2018
- Published by Elsevier in Clinica Chimica Acta
- Vol. 485, 218-223
Whole genome sequencing identifies a de novo 2.1 Mb balanced paracentric inversion disrupting FOXP1 and leading to severe intellectual disability
- Open Access
- 18 April 2017
- Published by Springer Nature in Molecular Psychiatry
- Vol. 23 (5) , 1356-1367
Ptchd1 deficiency induces excitatory synaptic and cognitive dysfunctions in mouse
Synapse development and neuronal activity represent fundamental processes for the establishment of cognitive function. Structural organization as well as signalling pathways from receptor stimulation to gene expression regulation are mediated by synaptic activity and misregulated in neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Deleterious mutations in the PTCHD1 (Patched domain containing 1) gene have been described in male patients with X-linked ID and/or ASD. The structure of PTCHD1 protein is similar to the Patched (PTCH1) receptor; however, the cellular mechanisms and pathways associated with PTCHD1 in the developing brain are poorly determined. Here we show that PTCHD1 displays a C-terminal PDZ-binding motif that binds to the postsynaptic proteins PSD95 and SAP102. We also report that PTCHD1 is unable to rescue the canonical sonic hedgehog (SHH) pathway in cells depleted of PTCH1, suggesting that both proteins are involved in distinct cellular signalling pathways. We find that Ptchd1 deficiency in male mice (Ptchd1-/y) induces global changes in synaptic gene expression, affects the expression of the immediate-early expression genes Egr1 and Npas4 and finally impairs excitatory synaptic structure and neuronal excitatory activity in the hippocampus, leading to cognitive dysfunction, motor disabilities and hyperactivity. Thus our results support that PTCHD1 deficiency induces a neurodevelopmental disorder causing excitatory synaptic dysfunction.
- 18 April 2017
- Published by Springer Nature in Molecular Psychiatry
- Vol. 23 (5) , 1356-1367
Open AccessPtchd1 deficiency induces excitatory synaptic and cognitive dysfunctions in mouse
Synapse development and neuronal activity represent fundamental processes for the establishment of cognitive function. Structural organization as well as signalling pathways from receptor stimulation to gene expression regulation are mediated by synaptic activity and misregulated in neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Deleterious mutations in the PTCHD1 (Patched domain containing 1) gene have been described in male patients with X-linked ID and/or ASD. The structure of PTCHD1 protein is similar to the Patched (PTCH1) receptor; however, the cellular mechanisms and pathways associated with PTCHD1 in the developing brain are poorly determined. Here we show that PTCHD1 displays a C-terminal PDZ-binding motif that binds to the postsynaptic proteins PSD95 and SAP102. We also report that PTCHD1 is unable to rescue the canonical sonic hedgehog (SHH) pathway in cells depleted of PTCH1, suggesting that both proteins are involved in distinct cellular signalling pathways. We find that Ptchd1 deficiency in male mice (Ptchd1-/y) induces global changes in synaptic gene expression, affects the expression of the immediate-early expression genes Egr1 and Npas4 and finally impairs excitatory synaptic structure and neuronal excitatory activity in the hippocampus, leading to cognitive dysfunction, motor disabilities and hyperactivity. Thus our results support that PTCHD1 deficiency induces a neurodevelopmental disorder causing excitatory synaptic dysfunction.
- Open Access
- 6 March 2014
- Vol. 20, 270-282
Gene regulation by PAX6: Structural-functional correlations of missense mutants and transcriptional control of Trpm3/miR-204
Pax6 is a key regulatory gene for eye, brain, and pancreas development. It acts as a transcriptional activator and repressor. Loss-of-function of Pax6 results in down- and upregulation of a comparable number of genes, although many are secondary targets. Recently, we found a prototype of a Pax6-binding site that acts as a transcriptional repressor. We also identified the Trpm3 gene as a Pax6-direct target containing the miR-204 gene located in intron 6. Thus, there are multiple Pax6-dependent mechanisms of transcriptional repression in the cell. More than 50 Pax6 missense mutations have been identified in humans and mice. Two of these mutations, N50K (Leca4) and R128C (Leca2), were analyzed in depth resulting in different numbers of regulated genes and different ratios of down- and upregulated targets. Thus, additional studies of these mutants are warranted to better understand the molecular mechanisms of the mutants’ action. Mutations in PAX6 and PAX6(5a), including G18W, R26G, N50K, G64V, R128C, and R242T, were generated with site-directed mutagenesis. A panel of ten luciferase reporters driven by six copies of Pax6-binding sites representing a spectrum of sites that act as repressors, moderate activators, and strong activators were used. Two additional reporters, including the Pax6-regulated enhancer from mouse Trpm3 and six copies of its individual Pax6-binding site, were also tested in P19 cells. PAX6 (N50K) acted either as a loss-of-function or neutral mutation. In contrast, PAX6 (R128C) and (R242T) acted as loss-, neutral, and gain-of-function mutations. With three distinct reporters, the PAX6 (N50K) mutation broke the pattern of effects produced by substitutions in the surrounding helices of the N-terminal region of the paired domain. All six mutations tested acted as loss-of-function using the Trpm3 Pax6-binding site. These studies highlight the complexity of Pax6-dependent transcriptional activation and repression mechanisms, and identify the N50K and R128C substitutions as valuable tools for testing interactions between Pax6, Pax6 (N50K), and Pax6 (R128C) with other regulatory proteins, including chromatin remodelers.
- 6 March 2014
- Vol. 20, 270-282
Open AccessGene regulation by PAX6: Structural-functional correlations of missense mutants and transcriptional control of Trpm3/miR-204
Pax6 is a key regulatory gene for eye, brain, and pancreas development. It acts as a transcriptional activator and repressor. Loss-of-function of Pax6 results in down- and upregulation of a comparable number of genes, although many are secondary targets. Recently, we found a prototype of a Pax6-binding site that acts as a transcriptional repressor. We also identified the Trpm3 gene as a Pax6-direct target containing the miR-204 gene located in intron 6. Thus, there are multiple Pax6-dependent mechanisms of transcriptional repression in the cell. More than 50 Pax6 missense mutations have been identified in humans and mice. Two of these mutations, N50K (Leca4) and R128C (Leca2), were analyzed in depth resulting in different numbers of regulated genes and different ratios of down- and upregulated targets. Thus, additional studies of these mutants are warranted to better understand the molecular mechanisms of the mutants’ action. Mutations in PAX6 and PAX6(5a), including G18W, R26G, N50K, G64V, R128C, and R242T, were generated with site-directed mutagenesis. A panel of ten luciferase reporters driven by six copies of Pax6-binding sites representing a spectrum of sites that act as repressors, moderate activators, and strong activators were used. Two additional reporters, including the Pax6-regulated enhancer from mouse Trpm3 and six copies of its individual Pax6-binding site, were also tested in P19 cells. PAX6 (N50K) acted either as a loss-of-function or neutral mutation. In contrast, PAX6 (R128C) and (R242T) acted as loss-, neutral, and gain-of-function mutations. With three distinct reporters, the PAX6 (N50K) mutation broke the pattern of effects produced by substitutions in the surrounding helices of the N-terminal region of the paired domain. All six mutations tested acted as loss-of-function using the Trpm3 Pax6-binding site. These studies highlight the complexity of Pax6-dependent transcriptional activation and repression mechanisms, and identify the N50K and R128C substitutions as valuable tools for testing interactions between Pax6, Pax6 (N50K), and Pax6 (R128C) with other regulatory proteins, including chromatin remodelers.